C

Can Fite Biopharma Ltd
TASE:CANF

Watchlist Manager
Can Fite Biopharma Ltd
TASE:CANF
Watchlist
Price: 1 ILS Market Closed
Market Cap: 31.5m ILS
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CANF stock under the Base Case scenario is hidden ILS. Compared to the current market price of 1 ILS, Can Fite Biopharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CANF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

13.8
P/S
P/S
Price to Sales
13.8
vs History
98
vs Industry
27
Median 3Y
37.7
Median 5Y
84
Industry
7.7
Forward
2.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-6
Industry
22.9
Forward
-0.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-4.5
Industry
21.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-4.5
Industry
22.7
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
98
vs Industry
13
Median 3Y
4.3
Median 5Y
8.8
Industry
3
More Details
6.7
EV/S
EV/S
Enterprise Value to Sales
6.7
vs History
98
vs Industry
26
Median 3Y
32.3
Median 5Y
75.1
Industry
8.2
Forward
1.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-6.6
Industry
5.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-6.6
Industry
5.9
Forward
-0.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-3.9
Industry
6.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-3.9
Industry
5
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
96
vs Industry
6
Median 3Y
3.8
Median 5Y
7.6
Industry
5.2
More Details

Multiples Across Competitors

CANF Competitors Multiples
Can Fite Biopharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Can Fite Biopharma Ltd
TASE:CANF
31.5m ILS 13.8 -1.2 -0.6 -0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 075 752.7 -161 957 -196 667.5 -194 423.2
US
Abbvie Inc
NYSE:ABBV
366.6B USD 6.3 98.5 16.2 23.5
US
US BioTec Inc
OTC:USBC
172.5B USD 0 0 0 0
US
Amgen Inc
NASDAQ:AMGN
155.2B USD 4.4 23.4 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
141.8B USD 4.9 22.5 10.5 14.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.4 -527.6 -574.5 -559.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
99.7B USD 8.7 27.4 20.2 21.1
AU
CSL Ltd
ASX:CSL
104.4B AUD 4.3 22.5 14.9 18.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 4.3 13.7 12.3 13.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
58.1B USD 23.6 -182.1 -455 -312.3
P/S Multiple
Revenue Growth P/S to Growth
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Average P/S: 3 407 789.1
13.8
440%
0
FR
Pharnext SCA
OTC:PNEXF
34 075 752.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
9%
0.7
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
4%
1.2
US
E
Epizyme Inc
F:EPE
2 067.4
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.7
10%
0.9
AU
CSL Ltd
ASX:CSL
4.3
6%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
5%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
23.6
41%
0.6
P/E Multiple
Earnings Growth PEG
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Average P/E: 34.7
Negative Multiple: -1.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 957 N/A N/A
US
Abbvie Inc
NYSE:ABBV
98.5
88%
1.1
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
23.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.5
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.4
N/A N/A
AU
CSL Ltd
ASX:CSL
22.5
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
6%
2.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -182.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Average EV/EBITDA: 15.4
Negative Multiple: -0.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 667.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.4
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.2
17%
1.2
AU
CSL Ltd
ASX:CSL
14.9
12%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -455 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Average EV/EBIT: 18.3
Negative Multiple: -0.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 423.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
28%
0.8
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.4
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.4
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.1
17%
1.2
AU
CSL Ltd
ASX:CSL
18.6
16%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -312.3 N/A N/A

See Also

Summary
CANF intrinsic value, competitors valuation, and company profile.
DCF Valuation
CANF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CANF stock valuation using valuation multiples.
Wall Street Estimates
CANF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CANF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 277,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.